Gemcitabine Bladder Instillation for Extended Dwell Time
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bladder cancer, particularly non-muscle invasive bladder cancer, face challenges with the short dwell time of intravesically administered chemotherapeutic agents like gemcitabine, leading to limited therapeutic benefit and systemic toxicity due to rapid voiding from the bladder, necessitating high doses that can cause adverse effects.
Innovation Solution
Local administration of gemcitabine to the bladder for an extended period, such as at least 24 hours, to enhance immune response and tumor microenvironment modulation, potentially combined with other agents like immunomodulatory drugs, to improve treatment efficacy and reduce recurrence and progression of bladder cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high doses of gemcitabine are administered intravesically to overcome short dwell time limitations, then therapeutic tissue levels are achieved, but systemic absorption increases causing gastrointestinal, bladder and bone marrow toxicity
Solution Approach 1:
The patent divides the bladder treatment into multiple smaller instillation sessions rather than single high-dose administration. The total therapeutic dose is segmented into multiple lower-dose applications delivered over several days, allowing sustained exposure without overwhelming systemic absorption in any single event.
Solution Approach 2:
The patent implements continuous or repeated intravesical instillation of gemcitabine over an extended period (multiple days to weeks). This continuous low-dose exposure maintains therapeutic levels in the bladder tissue while avoiding the peak systemic absorption that occurs with single high-dose administration.
2Ease of operation
If liquid formulations are voided from the bladder after short dwell times of 1 to 2 hours, then bladder comfort is maintained, but therapeutic benefit is limited
Solution Approach 1:
The patent employs periodic re-instillation of gemcitabine into the bladder at scheduled intervals (e.g., daily or multiple times per week). Each instillation delivers a fresh dose that contacts the tumor tissue during the brief dwell time, and the cumulative effect of repeated periodic exposure achieves therapeutic benefit without requiring prolonged single-dose retention.
3Quantity of substance
If high concentrations (40 mg/mL) and high doses (up to 2 grams per instillation) are used, then therapeutic tissue levels are achieved, but local tolerability issues and systemic absorption increase
Solution Approach 1:
The patent fundamentally changes the dosing parameters from high concentration/single high dose to low concentration/repeated lower doses. By adjusting the concentration parameter to lower levels (e.g., 1-10 mg/mL) and increasing the frequency parameter (multiple instillations over days), the patent achieves the same cumulative therapeutic exposure while reducing peak local irritation and systemic absorption.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods, devices, and kits related to treatment of urothelial carcinomas of the lower tract with antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treatment of urothelial carcinomas of the lower tract with an antimetabolite (such as gemcitabine) and an immunomodulating agent.